NCT01573598

Safety and Efficacy of Vilazodone in Major Depressive Disorder

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Relapse Prevention Study With Vilazodone in Patients With Major Depressive Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,219 (actual)
• Sponsor: Forest Laboratories · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Conditions

• Major Depressive Disorder

Interventions

Type	Name	Description
DRUG	Placebo	Matching placebo given orally, once per day
DRUG	Vilazodone	Vilazodone, 20 mg per day, oral administration
DRUG	Vilazodone	Vilazodone, 40 mg once per day, oral administration

Timeline

• Start date: 2012-04-01
• Primary completion: 2014-10-01
• Completion: 2015-01-01
• First posted: 2012-04-09
• Last updated: 2015-05-18

Locations

75 sites across 8 countries: United States, Bulgaria, Finland, Germany, Romania, Russia, Serbia, Ukraine